Literature DB >> 15475360

Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system.

Elisabetta del Re1, Yisrael Sidis, David A Fabrizio, Herbert Y Lin, Alan Schneyer.   

Abstract

Activins and inhibins compose a heterogeneous subfamily within the transforming growth factor-beta (TGF-beta) superfamily of growth and differentiation factors with critical biological activities in embryos and adults. They signal through a heteromeric complex of type II, type I, and for inhibin, type III receptors. To characterize the affinity, specificity, and activity of these receptors (alone and in combination) for the inhibin/activin subfamily, we developed a cell-free assay system using soluble receptor-Fc fusion proteins. The soluble activin type II receptor (sActRII)-Fc fusion protein had a 7-fold higher affinity for activin A compared with sActRIIB-Fc, whereas both receptors had a marked preference for activin A over activin B. Although inhibin A and B binding was 20-fold lower compared with activin binding to either type II receptor alone, the mixture of either type II receptor with soluble TGF-beta type III receptor (TbetaRIII; betaglycan)-Fc reconstituted a soluble high affinity inhibin receptor. In contrast, mixing either soluble activin type II receptor with soluble activin type I receptors did not substantially enhance activin binding. Our results support a cooperative model of binding for the inhibin receptor (ActRII.sTbetaRIII complex) but not for activin receptors (type II + type I) and demonstrate that a complex composed of activin type II receptors and TbetaRIII is both necessary and sufficient for high affinity inhibin binding. This study also illustrates the utility of this cell-free system for investigating hypotheses of receptor complex mechanisms resulting from crystal structure analyses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475360     DOI: 10.1074/jbc.M408090200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

2.  Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.

Authors:  Kyosuke Hino; Kazuhiko Horigome; Megumi Nishio; Shingo Komura; Sanae Nagata; Chengzhu Zhao; Yonghui Jin; Koichi Kawakami; Yasuhiro Yamada; Akira Ohta; Junya Toguchida; Makoto Ikeya
Journal:  J Clin Invest       Date:  2017-07-31       Impact factor: 14.808

3.  Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb.

Authors:  Dianne Sako; Asya V Grinberg; June Liu; Monique V Davies; Roselyne Castonguay; Silas Maniatis; Amy J Andreucci; Eileen G Pobre; Kathleen N Tomkinson; Travis E Monnell; Jeffrey A Ucran; Erik Martinez-Hackert; R Scott Pearsall; Kathryn W Underwood; Jasbir Seehra; Ravindra Kumar
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

Review 4.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

Review 5.  Emerging roles for the transforming growth factor-{beta} superfamily in regulating adiposity and energy expenditure.

Authors:  Nader Zamani; Chester W Brown
Journal:  Endocr Rev       Date:  2010-12-20       Impact factor: 19.871

6.  Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.

Authors:  Sonia Vallet; Siddhartha Mukherjee; Nileshwari Vaghela; Teru Hideshima; Mariateresa Fulciniti; Samantha Pozzi; Loredana Santo; Diana Cirstea; Kishan Patel; Aliyah R Sohani; Alex Guimaraes; Wanling Xie; Dharminder Chauhan; Jesse A Schoonmaker; Eyal Attar; Michael Churchill; Edie Weller; Nikhil Munshi; Jasbir S Seehra; Ralph Weissleder; Kenneth C Anderson; David T Scadden; Noopur Raje
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

7.  Activin signaling: effects on body composition and mitochondrial energy metabolism.

Authors:  Liunan Li; Joseph J Shen; Juan C Bournat; Lihua Huang; Abanti Chattopadhyay; Zhihong Li; Chad Shaw; Brett H Graham; Chester W Brown
Journal:  Endocrinology       Date:  2009-04-23       Impact factor: 4.736

8.  ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.

Authors:  Sarah J Hatsell; Vincent Idone; Dana M Alessi Wolken; Lily Huang; Hyon J Kim; Lili Wang; Xialing Wen; Kalyan C Nannuru; Johanna Jimenez; Liqin Xie; Nanditha Das; Genevieve Makhoul; Rostislav Chernomorsky; David D'Ambrosio; Richard A Corpina; Christopher J Schoenherr; Kieran Feeley; Paul B Yu; George D Yancopoulos; Andrew J Murphy; Aris N Economides
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

9.  A soluble activin type IIA receptor induces bone formation and improves skeletal integrity.

Authors:  R Scott Pearsall; Ernesto Canalis; Milton Cornwall-Brady; Kathryn W Underwood; Brendan Haigis; Jeffrey Ucran; Ravindra Kumar; Eileen Pobre; Asya Grinberg; Eric D Werner; Vaida Glatt; Lisa Stadmeyer; Deanna Smith; Jasbir Seehra; Mary L Bouxsein
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-06       Impact factor: 11.205

10.  Production, Isolation, and Structural Analysis of Ligands and Receptors of the TGF-β Superfamily.

Authors:  Tao Huang; Andrew P Hinck
Journal:  Methods Mol Biol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.